標(biāo)題：Research Grade Cetuximab 西妥昔單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/10059.html

名稱：Research Grade Cetuximab西妥昔單抗

別名：Cetuximab西妥昔單抗，Fab C225, IMC-225, cetuximab-IR700

CAS: 205923-56-4

貨號：DHB86902

適用物種：Human

寄主物種：Chimeric

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG1-kappa

應(yīng)用：Research Grade Biosimilar

UniProt：P00533

靶點(diǎn)：HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB

用途范圍：僅用于科研

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻(xiàn)：

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. PMID: 36546659

Cetuximab for treating non-small cell lung cancer. PMID: 29534625

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. PMID: 34775496

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. PMID: 30449625

Cetuximab-induced bullous pemphigoid. PMID: 36939515

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. PMID: 36522816

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. PMID: 36117191

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. PMID: 30199311

Cetuximab every 2 weeks versus standard weekly dosing administration schedule. PMID: 37850363

Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. PMID: 34245856

Cetuximab and the Head and Neck Squamous Cell Cancer. PMID: 29332581

Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. PMID: 35986743

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS(G12D) Inhibitor, in Colorectal Cancer Treatment. PMID: 37772552

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. PMID: 37721754

Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event. PMID: 27378078

Cetuximab monotherapy for relapsing high-grade mucoepidermoid carcinoma: A case report and review of the literature. PMID: 32518035

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. PMID: 33989949

Cetuximab: Its role in patients unfit for cisplatin. PMID: 34864298

3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis. PMID: 37558749

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. PMID: 37557179

Cost-effectiveness of cetuximab for colorectal cancer. PMID: 27750444

Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. PMID: 36899869

Cetuximab associated dermal filler reaction. PMID: 31451454

A Critical Review of Properties and Analytical/Bioanalytical Methods for Characterization of Cetuximab. PMID: 30869993

Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. PMID: 25794489

Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700. PMID: 37817415

Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK. PMID: 37337933

Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis. PMID: 36253001

Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. PMID: 27340349

Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer. PMID: 37010248

Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer. PMID: 36932871

Cetuximab and Radiotherapy in Laryngeal Preservation. PMID: 28006053

Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms? PMID: 32275949

Trichomegaly Induced by Cetuximab: Case Series and Review the Literature. PMID: 26079631

Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. PMID: 31678385

Pinnae and facial hypertrichosis induced by cetuximab. PMID: 35821579

Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. PMID: 31578019

The role of IgE specific for galactose-alpha-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis. PMID: 33288791

Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy. PMID: 33222742

Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients. PMID: 37442917